Skip to main content
Clinical Trials/NCT02875743
NCT02875743
Completed
Phase 4

Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis

King's College Hospital NHS Trust1 site in 1 country120 target enrollmentDecember 7, 2016

Overview

Phase
Phase 4
Intervention
Posaconazole
Conditions
Aplastic Anemia
Sponsor
King's College Hospital NHS Trust
Enrollment
120
Locations
1
Primary Endpoint
Cumulative incidence of IFD in all treatment groups (aplastic anaemia with IST, chemotherapy only, RIC allograft)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Invasive fungal disease (IFD) is an important cause of mortality and morbidity in patients undergoing intensive chemotherapy or transplantation.

This current study aims to assess the impact of prophylactically using the broad-spectrum anti-fungal agent posaconazole on the incidence of IFD in high risk patients with aplastic anaemia and those undergoing intensive chemotherapy, for example for acute myeloid leukaemia, and allogeneic stem cell transplantation.

Registry
clinicaltrials.gov
Start Date
December 7, 2016
End Date
October 31, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
King's College Hospital NHS Trust
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Posaconazole

Intervention: Posaconazole

Outcomes

Primary Outcomes

Cumulative incidence of IFD in all treatment groups (aplastic anaemia with IST, chemotherapy only, RIC allograft)

Time Frame: 24 weeks

Study Sites (1)

Loading locations...

Similar Trials